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Possible Roles of IL-33 in Periodontal
Diseases: Porphyromonas gingivalis Induced
IL-33 in Human Gingival Epithelial Cells
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Abstract In the oral mucosa, epithelial cells work not only as a physical barrier to
pathogens, but also play a pivotal role in initiating immune responses to microbes.
Interleukin (IL)-33, a member of the IL-1 family, is constitutively expressed in
epithelial cells and amplifies Th2-type inflammatory immune responses. We found
that IL-33 was detected in the inflamed gingival epithelium from chronic periodon-
titis patients, and periodontopathic Porphyromonas gingivalis strongly increased
expressions of IL-33 mRNA and molecules in human gingival epithelial cells. In
contrast, fimbriae, a lipopeptide and lipopolysaccharide derived from P. gingivalis
were not active in this respect. Protease inhibitors specific for gingipains efficiently
inhibited the induction of IL-33 mRNA by stimulation with P. gingivalis. Further-
more, P. gingivalis KDP136, a gingipains-null mutant, did not increase IL-33
mRNA expression. We also demonstrated that P. gingivalis upregulated IL-33
mRNA expression through protease-activated receptor-2, phospholipase C,
mitogen-activated protein kinase p38 and NF-κB. IL-33 is suggested to negatively
regulate antimicrobial peptide LL-37, resulting in attenuation of innate immune
responses of gingival epithelial cells in chronic periodontitis. Possible roles of
IL-33 in inflammation in the oral mucosa are discussed.
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In mucosal immune systems, including the oral mucosa, epithelial cells work not
only as a physical barrier to bacterial pathogens, but also play a pivotal role in
initiating and amplifying Th2-type immune responses in response to bacterial
components [1, 2]. Epithelial cells produce interleukin (IL)-33, IL-25, and thymic
stromal lymphopoietin, which may be involved in the development and regulation
of Th2-type inflammatory responses. IL-33 is a member of the IL-1 cytokine
family, and is constitutively expressed in epithelial cells, endothelial cells and
fibroblasts [3]. IL-33 consists of two domains: a non-classical homeodomain-like
helix-turn-helix DNA-binding domain, which consists of a chromatin-binding
motif (CBM) and a nuclear localization sequence (NLS), and an IL-1-like domain
[4] (Fig. 25.1a). IL-33 localizes in the nuclei of resting epithelial cells and acts as an
alarmin when released from necrotic cells (Fig. 25.1b). IL-33 has a protective role
in inflammatory bowel disease [7] and in the initiation of Toxoplasma infection that
polarizes adaptive responses towards a Th2-biased response, which is protective in
this disease [8]. In contrast, a lot of evidence suggests that IL-33 is also involved in
the development of chronic inflammatory diseases such as arthritis [9]. IL-33
signals through the IL-33 receptor (IL-33R), which consists of heterodimers of
ST2 and IL-1 receptor accessory protein (IL-1RAcP) [5, 6] (Fig. 25.2). IL-33 upon
binding to ST2 induces the recruitment of IL-1RAcP and myeloid differentiation
primary-response protein 88 (MyD88) to the Toll/IL-1R (TIR) domain in the
a
b
Fig. 25.1 (a) Structure of IL-33 protein. IL-33 is a 30-kDa protein that consists of 270 amino
acids. IL-33 consists of two domains: a helix-turn-helix domain and an IL-1-like domain. The
helix-turn-helix domain contains a chromatin-binding motif (CBM) and a nuclear localization
signal (NLS). (b) Release of IL-33. Active form of IL-33 is thought to be released by necrosis.
IL-33 is inactivated by cleaving with caspase-3 or caspase-7 during apoptosis. Based on Martin,
Oboki et al. and Palmer and Gabay [4–6]
294 H. Tada et al.
cytoplasmic region of ST2. The MyD88 and TRAF6 complex activates NF-κB- and
MAP kinase-mediated signaling pathways [5, 6].
Porphyromonas gingivalis is a periodontopathic pathogen in chronic periodon-
titis and has a variety of virulence factors that induce proinflammatory cytokines
leading to chronic inflammation, resulting in destruction of periodontal tissues. In
the dental/oral field, only limited information on IL-33 is available (see Table 25.1).
TNF-α induces IL-33 expression in human gingival fibroblasts [12], although
whether IL-33 expression is increased in the periodontal tissues in chronic peri-
odontitis patients and the functions of IL-33 in the modulation of chronic periodon-
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Table 25.1 Articles on IL-33 in oral/dental science
Finding Reference
IL-33 mRNA and protein expressions are enhanced by P. gingivalis
LPS in human monocytes
Nile et al. 2010 [10]
IL-33 protein expressions are not differentiated from human gingival
crevicular fluid, saliva, or plasma in chronic periodontitis
Buduneli et al. 2012 [11]
IL-33 protein expression is enhanced by TNF-α in human gingival
fibroblasts
Beklen et al. 2013 [12]
IL-33 protein expression is not detected from human gingival
crevicular fluid in gingivitis or periodontitis
Papathanasiou
et al. 2014 [13]
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expression in human gingival epithelial cells in response to P. gingivalis based on
our recent studies, and discusses possible roles of IL-33 expressed in gingival
epithelial cells in relation to the pathogenesis of chronic periodontitis.
25.2 Expression of IL-33 in Periodontal Tissues
from Chronic Periodontitis Patients
We first examined whether inflamed gingival tissues from chronic periodontitis
patients expressed IL-33 by immunohistochemical studies using an anti-human
IL-33 monoclonal antibody (mAb). As expected, IL-33 was strongly expressed in
the cytoplasm of the inflamed gingival epithelium from chronic periodontitis
patients, but only weakly detected in the normal gingival epithelium from
healthy individuals. Unlike the expression of IL-33 in the gingival epithelium,
IL-33 expression in the lamina propria of gingival tissues was only weakly
observed. IL-33 expression is possibly upregulated in epithelial, mesenchymal,
and myeloid cells in response to proinflammatory stimuli, pathogen-associated
molecular patterns, and pathogens [5]. These findings suggest that gingival
epithelial cells are capable of inducing IL-33 expression upon infection with
periodontal pathogens.
25.3 Possible Induction of IL-33 by Gingipains from
P. gingivalis in Gingival Epithelial Cells
25.3.1 P. gingivalis Induces IL-33 mRNA Expression
in Human Gingival Epithelial Cells in Culture
As P. gingivalis is implicated as a major pathogenic bacteria for chronic periodon-
titis [14], we examined the effect of P. gingivalis infection on IL-33 mRNA
expression in human gingival epithelial cells in culture. The IL-33 mRNA expres-
sion was increased 20-fold at 48 h after stimulation with P. gingivalis W83 in
Ca9-22 cells, which is a human gingival epithelial cell line established from
squamous cell carcinoma. Pretreatment of the cells with cycloheximide, a protein
synthesis inhibitor, blocked the induction of IL-33 mRNA levels, suggesting that de
novo protein synthesis was required for P. gingivalis-mediated IL-33 mRNA
induction. Nile et al. [10] reported that P. gingivalis LPS induced IL-33 expression
in human monocytes. Therefore, we examined the possible IL-33 mRNA-inducing
capacity of P. gingivalis-related specimens; fimbriae (Toll-like receptor (TLR)
2 ligand [15]) and LPS (TLR2 and 4 ligand [16]) prepared from P. gingivalis,
and synthetic P. gingivalis-type lipopeptide PGTP2-RL (TLR2/1 ligand [17]).
Unlike P. gingivalis whole cells, fimbriae and lipopeptide were completely
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inactive, and LPS specimens were only weakly active in this respect. These results
suggest that gingival epithelial cells respond to P. gingivalis rather than TLR
ligands for induction of IL-33 mRNA.
25.3.2 Involvement of Gingipains in the Induction of IL-33
mRNA Expression in Human Gingival Epithelial
Cells by P. gingivalis
P. gingivalis produces two types of arginine-specific cysteine proteinases
(Arg-gingipains, RgpA and RgpB) and a lysine-specific cysteine proteinase
(Lys-gingipain, Kgp) [18]. Gingipains are localized to a cell-associated form, a
soluble form, and released as outer membrane blebs [18]. We next examined
whether enzymatic activities of gingipains are involved in the IL-33-inducing
capacity in Ca9-22 cells and primary oral epithelial cells. The induction of IL-33
mRNA expression by P. gingivalis W83 in the two types was completely and
significantly inhibited by FPR-cmk (Rgp inhibitor) and KYT-36 (Kgp inhibitor),
respectively. Furthermore, P. gingivalis KDP136, a gingipains-null mutant, unlike
P. gingivalis ATCC 33277, a wild-type parent strain of KDP136, did not induce
IL-33 mRNA expression in either cell type. P. gingivalis-induced IL-33 mRNA
expression was abolished by heat treatment (70 C, 1 h) to inactivate enzymatic
activities of P. gingivalis. We confirmed intact proteolytic activities for Rgps and
Kgp in the whole cells of P. gingivalis W83 and ATCC 33277, but not in those of
P. gingivalis KDP136. These observations suggest that the proteolytic activity of
gingipains is essential for the induction of IL-33 mRNA expression by P. gingivalis
in human gingival epithelial cells.
25.3.3 Induction of the IL-33 Molecule by P. gingivalis
in Human Gingival Epithelial Cells
Next, we examined whether P. gingivalis induced IL-33 expression in human
gingival epithelial cells using an immunoblot analysis. IL-33 expression in
Ca9-22 cells was increased tenfold with a peak at 4 days by stimulation with
whole cell preparations of P. gingivalis. Epithelial cells constitutively express
IL-33 in their nuclei under resting conditions [19]. IL-33 is a nuclear protein that
is also released into the extracellular environment. To further determine whether
P. gingivalis-induced IL-33 was accumulated in the nuclei or the cytoplasm, we
analyzed the location of IL-33 protein in Ca9-22 cells after stimulation with
P. gingivalis using immunocytochemical analysis. Although IL-33 was constitu-
tively expressed in the resting cells, IL-33 molecules accumulated in the cytoplasm
of the cells when they were stimulated with P. gingivalis for 4 days. However, the
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released IL-33 level was quite low (approximately 30 pg/mL), even after stimula-
tion with P. gingivaliswhole cells. IL-33 is not detected in viable human monocytic
cells, even upon stimulation with P. gingivalis LPS [10]. Furthermore, IL-33 levels
in gingival crevicular fluid (GCF) are not different between chronic periodontitis
patients and healthy controls [11]. In fact, IL-33 is not detected in the GCF of
inflamed regions from chronic periodontitis patients [13]. Further studies are
required to elucidate the fate of IL-33 induced by P. gingivalis in gingival epithelial
cells, which may modulate the innate immune functions of the cells in infected
periodontal lesions.
25.4 PAR-2-p38/NF-κB-Mediated Signals in IL-33
Induction
25.4.1 Role of PAR-2 in the Induction of IL-33 by Gingipains
Proteinase-activated receptor-2 (PAR-2) is a seven-transmembrane domain recep-
tor family which couples to G-proteins [20]. Rgps are capable of activating PAR-2
expressed on human gingival epithelial cells, which produce proinflammatory
cytokines [21]. We examined the possible involvement of PAR-2 in P. gingivalis-
induced IL-33 mRNA expression. Ca9-22 cells constitutively expressed PAR-1,
2,3, and 4 mRNA. PAR-2 mRNA expression was increased upon stimulation
with P. gingivalis W38 in Ca9-22 cells. Next, we performed inhibition of PAR-2
mRNA expression by RNA interference using a PAR-2-specific small interference
RNA (siRNA). The induction of IL-33 mRNA by P. gingivalis W83 was partially
inhibited in PAR-2 siRNA-transfected cells. PAR-2 is activated by a tethered ligand
when cleaved by protease. A PAR-2 agonist peptide based on the tethered ligand
sequences can activate PAR-2 in a proteolysis-independent manner. However, the
PAR-2 agonist peptide was not able to induce IL-33 mRNA in Ca9-22 cells.
Pretreatment of the cells with cytochalasin D, a particle internalization inhibitor,
inhibited the IL-33 mRNA induction by P. gingivalis. These findings suggested that
both proteolytic activation of PAR-2 by gingipains and the endocytosis of
P. gingivalis are required for the up-regulation of IL-33 expression induced by
P. gingivalis in oral epithelial cells. P. gingivalis enters gingival epithelial cells by
endocytosis, which mediates binding of Rgp to the cells [22]. It must be noted that
gingipains are required for maturation of P. gingivalis fimbriae [23], which is
essential for internalization of the bacterium into epithelial cells [24]. However,
endocytosis of both PAR-2 and P. gingivalis are probably required for the
up-regulation of IL-33 in gingival epithelial cells.
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25.4.2 Involvement of PLC in the Induction of IL-33
by Gingipains
Because PAR-2 has been reported to be coupled to G protein, leading to activation
of phospholipase C (PLC) [25, 26], we examined whether or not the PLC pathway
is involved in P. gingivalis-induced IL-33 mRNA expression in Ca9-22 cells. The
cells were pretreated with U-73122, a PLC inhibitor, and then stimulated
P. gingivalis W83 for 48 h. The pretreatment significantly inhibited the
P. gingivalis-induced IL-33 mRNA expression. In contrast, a protein kinase C
(PKC) inhibitor, GF-109203X, did not inhibit either the basal level of IL-33 or
the P. gingivalis-induced increase in IL-33. These findings suggest that
P. gingivalis-induced up-regulation of IL-33 expression is mediated via a PAR-2-
PLC-signaling pathway.
25.4.3 Involvement of p38 and NF-κB in the Induction
of IL-33 by Gingipains
As p38 and NF-κB are implicated in PAR-2 signaling [27], we first confirmed p38
phosphorylation in Ca9-22 cells stimulated with P. gingivalis W83. Then, we
demonstrated that p38 signaling is involved in P. gingivalis-induced IL-33
mRNA expression using SB203580, a p38 inhibitor. In contrast, the P. gingivalis
IL-33 mRNA expression was not inhibited by PD98059, an ERK1/2 inhibitor, or
SP600125, a JNK inhibitor. Further, we demonstrated that gingipains are respon-
sible for p38 activation caused by whole cells of P. gingivalis because p38 phos-
phorylation induced by P. gingivalis W83 was completely inhibited when
P. gingivalis was treated with Rgp inhibitor FPR-cmk plus Kgp inhibitor
KYT-36. In addition, p38 phosphorylation was not observed in the cells stimulated
with P. gingivalis KDP136, a gingipains-null mutant.
Next, we demonstrated NF-κB activation in Ca9-22 cells stimulated with
P. gingivalis W83 using a luciferase reporter assay. We demonstrated that NF-κB
signaling is involved in P. gingivalis-induced IL-33 mRNA expression because
pretreatment of cells with PDTC, an NF-κB inhibitor, significantly inhibited
P. gingivalis-induced IL-33 mRNA expression. The NF-κB activities induced by
P. gingivalis W83 were markedly diminished by FPR-cmk plus KYT-36, and the
NF-κB activation was attenuated in the cells stimulated with P. gingivalis KDP136,
indicating that gingipains are responsible for NF-κB activation caused by whole
cells of P. gingivalis. Taken together, we demonstrated that the P. gingivalis-
derived gingipain-mediated IL-33 increase was dependent on PAR-2-PLC-p38/
NF-κB signaling (Fig. 25.3).
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25.5 Future Prospects: Possible Roles of IL-33 in Gingival
Epithelial Cells in Chronic Periodontitis
Gingival epithelial cells play integral roles in innate immune defense by sensing
periodontal pathogens, maintaining a physical barrier, and expressing antimicrobial
peptides (AMPs) [28]. AMPs constitute an important component in the innate
immune response. In humans, two main classes of cationic AMPs, the cathelicidins
and the defensins, are expressed in a various type of cells, such as epithelial cells,
neutrophils, and macrophages. LL-37, a 37-residue mature antimicrobial peptide
with two leucine residues, is a 37 amino acid peptide derived from human
cathelicidin, a cationic antimicrobial peptide of 18-kDa (CAP18). The peptide is
mainly produced by epithelial cells and neutrophils [29] and detected in GCF [30].
Human β-defensin-2 (hBD-2), an antimicrobial peptide of the β-defensin family, is
induced by gingipains through PAR-2 in gingival epithelial cells [31]. It has been
reported that hBD-2 production is down-regulated by pretreatment with IL-33 in
human foreskin keratinocytes [32]. Endogenous expression of LL-37 plays an
important role in intracellular killing of mycobacteria in macrophages [33].
To address whether development of chronic periodontits is attributable to IL-33,
we examined the influence of P. gingivalis-mediated IL-33 production on the
induction of LL-37 in human gingival epithelial cells. Indeed, we found that
P. gingivalis-induced CAMP (LL-37 gene) mRNA expression was up-regulated
in IL-33 siRNA-transfected Ca9-22 cells. LL-37 is capable of proteolytically
degradation by gingipains secreted by P. gingivalis; however, the antibacterial







Fig. 25.3 Role of
gingipains in the induction
of IL-33 via PAR-2-p38/
NF-κB-mediated signals
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These findings indicate that IL-33 may attenuate antimicrobial immune responses
by epithelial cells against bacterial mucosal infections.
In this study, we revealed that P. gingivalis induced IL-33 via PAR-2-PLC-p38/
NF-κB signaling pathways and that the IL-33 down-regulated LL-37 expression in
human gingival epithelial cells. These findings suggest evasion of innate immune
responses by P. gingivalis is due to inhibition of antimicrobial peptide expression
(Fig. 25.4). Further studies are necessary to elucidate the role of intracellular IL-33
in maintaining host defense mechanisms in gingival epithelial cells against peri-
odontal diseases.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
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